Related Experiment Video

Updated: Jul 11, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 15, 2014

Clinical experience with itraconazole in systemic fungal infections

M Boogaerts1, J Maertens

  • 1Department of Haematology, University Hospital Gasthuisberg, Leuven, Belgium. marc.boogaerts@med.kuleuven.ac.be

Drugs
|February 24, 2001
PubMed

Insights

New itraconazole formulations offer effective prophylaxis and treatment for systemic fungal infections in immunocompromised patients. These options demonstrate reliable absorption and improved outcomes compared to other antifungals.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Systemic fungal infections pose a significant threat to immunocompromised individuals.
  • Itraconazole is a broad-spectrum antifungal agent with established efficacy.
  • New oral and intravenous formulations of itraconazole enhance its therapeutic utility.

Purpose of the Study:

  • To evaluate the efficacy and safety of new itraconazole formulations.
  • To assess itraconazole's effectiveness in prophylaxis and treatment of systemic fungal infections.
  • To compare itraconazole with other antifungal agents in specific patient populations.

Main Methods:

  • Clinical trials involving patients with hematological malignancy, HIV infection, and transplant recipients.
  • Administration of itraconazole oral solution (5 mg/kg/day) and intravenous itraconazole solution.
  • Comparison with placebo, fluconazole suspension, oral amphotericin-B, and intravenous amphotericin-B.

Main Results:

  • Itraconazole oral solution demonstrated superior efficacy in preventing fungal infections in patients with hematological malignancy compared to placebo, fluconazole, and oral amphotericin-B.
  • Intravenous itraconazole solution showed comparable efficacy to intravenous amphotericin-B with fewer adverse events.
  • Reliable absorption of itraconazole oral solution was confirmed in various at-risk patient groups, including those with HIV and neutropenia.

Conclusions:

  • New itraconazole formulations (oral and intravenous) are effective for prophylaxis and treatment of systemic fungal infections.
  • Itraconazole offers a well-tolerated and effective alternative to existing antifungal therapies.
  • These formulations improve therapeutic options for immunocompromised patients at high risk for fungal infections.

More Related Videos

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...